日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations.

ATR激酶抑制剂Elimusertib单药或联合治疗对具有DNA损伤反应通路和其他基因组改变的肿瘤的疗效

Varadarajan Kaushik, Cruz Pico Christian X, Evans Kurt W, Raso Maria Gabriela, Rizvi Yasmeen Qamar, Zheng Xiaofeng, Chachad Dhruv, DiPeri Timothy P, Wang Bailiang, Scott Stephen M, Zhao Ming, Akcakanat Argun, Wengner Antje M, Yap Timothy A, Meric-Bernstam Funda

Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts

新型双特异性抗HER2抗体Zanidatamab在患者来源异种移植模型中的联合临床试验

DiPeri, Timothy P; Evans, Kurt W; Wang, Bailiang; Zhao, Ming; Akcakanat, Argun; Raso, Maria Gabriela; Rizvi, Yasmeen Q; Zheng, Xiaofeng; Korkut, Anil; Varadarajan, Kaushik; Uzunparmak, Burak; Dumbrava, Ecaterina E; Pant, Shubham; Ajani, Jaffer A; Pohlmann, Paula R; Jensen, V Behrana; Javle, Milind; Rodon, Jordi; Meric-Bernstam, Funda

Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.

MAPK通路趋同改变介导FGFR2融合阳性胆管癌对FGFR抑制剂的获得性耐药

DiPeri Timothy P, Zhao Ming, Evans Kurt W, Varadarajan Kaushik, Moss Tyler, Scott Stephen, Kahle Michael P, Byrnes Charnel C, Chen Huiqin, Lee Sunyoung S, Halim Abdel-Baset, Hirai Hiroshi, Wacheck Volker, Kwong Lawrence N, Rodon Jordi, Javle Milind, Meric-Bernstam Funda

Discordance of HER2 Expression and/or Amplification on Repeat Testing

重复检测中HER2表达和/或扩增不一致

DiPeri, Timothy P; Kong, Kathleen; Varadarajan, Kaushik; Karp, Daniel D; Ajani, Jaffer A; Pant, Shubham; Press, Michael F; Piha-Paul, Sarina A; Dumbrava, Ecaterina E; Meric-Bernstam, Funda

Total neoadjuvant therapy for locally advanced gastric cancer: too much of a good thing?

局部晚期胃癌的新辅助治疗是否过犹不及?

DiPeri, Timothy P; Gong, Jun; Burch, Miguel

Prospective Implementation of Standardized Post-Hepatectomy Care Pathways to Reduce Opioid Prescription Volume after Inpatient Surgery

前瞻性实施标准化肝切除术后护理路径以减少住院手术后阿片类药物处方量

DiPeri, Timothy P; Newhook, Timothy E; Arvide, Elsa M; Dewhurst, Whitney L; Bruno, Morgan L; Chun, Yun Shin; Tran Cao, Hop S; Lee, Jeffrey E; Vauthey, Jean-Nicolas; Tzeng, Ching-Wei D

Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma

BRAF V600E突变型转移性肝内胆管癌患者接受BRAF和MEK双重抑制治疗后出现皮质类固醇难治性肌炎

DiPeri, Timothy P; Demirhan, Mehmet; Karp, Daniel D; Fu, Siqing; Hong, David S; Subbiah, Vivek; Lim, Joann; Ballester, Leomar Y; Tayar, Jean H; Suarez-Almazor, Maria E; Javle, Milind; Meric-Bernstam, Funda

Prognostic significance of preoperative and postoperative CA 19-9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first

新辅助治疗或手术治疗胰腺腺癌患者术前和术后CA 19-9正常化的预后意义

DiPeri, Timothy P; Newhook, Timothy E; Prakash, Laura R; Ikoma, Naruhiko; Maxwell, Jessica E; Kim, Michael P; Lee, Jeffrey E; Katz, Matthew H G; Tzeng, Ching-Wei D

A prospective feasibility study evaluating the 5x-multiplier to standardize discharge prescriptions in cancer surgery patients

一项前瞻性可行性研究,旨在评估 5 倍乘数法在癌症手术患者出院处方标准化中的应用

DiPeri, Timothy P; Newhook, Timothy E; Day, Ryan W; Chiang, Yi-Ju; Dewhurst, Whitney L; Arvide, Elsa M; Bruno, Morgan L; Scally, Christopher P; Roland, Christina L; Katz, Matthew H G; Vauthey, Jean-Nicolas; Chang, George J; Badgwell, Brian D; Perrier, Nancy D; Grubbs, Elizabeth G; Lee, Jeffrey E; Tzeng, Ching-Wei D

Next generation sequencing for biliary tract cancers

胆道癌的下一代测序

DiPeri, Timothy P; Javle, Milind M; Meric-Bernstam, Funda